ATE541588T1 - Konjugat von perphenazin und gaba und seine verwendungen - Google Patents

Konjugat von perphenazin und gaba und seine verwendungen

Info

Publication number
ATE541588T1
ATE541588T1 AT02772790T AT02772790T ATE541588T1 AT E541588 T1 ATE541588 T1 AT E541588T1 AT 02772790 T AT02772790 T AT 02772790T AT 02772790 T AT02772790 T AT 02772790T AT E541588 T1 ATE541588 T1 AT E541588T1
Authority
AT
Austria
Prior art keywords
residue
chemical moiety
psychotic drug
perphenazine
gaba
Prior art date
Application number
AT02772790T
Other languages
English (en)
Inventor
Abraham Nudelman
Ada Rephaeli
Irit Gil-Ad
Abraham Weizman
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE541588T1 publication Critical patent/ATE541588T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT02772790T 2001-09-27 2002-09-29 Konjugat von perphenazin und gaba und seine verwendungen ATE541588T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32493601P 2001-09-27 2001-09-27
PCT/IL2002/000795 WO2003026563A2 (en) 2001-09-27 2002-09-29 Conjugated anti-psychotic drugs and uses thereof

Publications (1)

Publication Number Publication Date
ATE541588T1 true ATE541588T1 (de) 2012-02-15

Family

ID=23265759

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772790T ATE541588T1 (de) 2001-09-27 2002-09-29 Konjugat von perphenazin und gaba und seine verwendungen

Country Status (10)

Country Link
EP (2) EP2275143B1 (de)
JP (3) JP4521187B2 (de)
KR (4) KR20100097224A (de)
CN (2) CN100558365C (de)
AT (1) ATE541588T1 (de)
CA (1) CA2461663A1 (de)
ES (2) ES2379544T3 (de)
IL (2) IL161083A0 (de)
MX (1) MXPA04002912A (de)
WO (1) WO2003026563A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
KR20100097224A (ko) * 2001-09-27 2010-09-02 라모트 앳 텔 아비브 유니버시티 리미티드 접합된 항-정신병 약물 및 그의 용도
ES2400772T3 (es) * 2005-06-07 2013-04-12 Ramot At Tel Aviv University Ltd. Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
CN101247837B (zh) * 2005-06-07 2013-03-20 特拉维夫大学拉莫特有限公司 新的轭合精神活性药物的盐及其制备方法
US9278947B2 (en) 2006-06-22 2016-03-08 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
CN101506188B (zh) * 2006-06-22 2014-01-15 雷蒙特亚特特拉维夫大学有限公司 作为具外周***限制活性药物的五羟色胺再摄取抑制剂
EP2051735B1 (de) * 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Konjugate mit einem psychotropische heilmittel oder einem gaba agonist und eine organische säure und ihre behandlung von schmerzen und andere erkrankungen des zns
US7632836B2 (en) * 2006-11-30 2009-12-15 Cenerx Biopharma, Inc. Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
NZ590616A (en) 2008-06-20 2012-09-28 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
AU2009302241B2 (en) * 2008-10-08 2015-10-29 Xgene Pharmaceutical Inc. GABA conjugates and methods of use thereof
WO2011070579A1 (en) * 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
AU2014202425B2 (en) * 2009-12-31 2015-11-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
CN102781236B (zh) 2009-12-31 2015-01-07 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
US8377929B2 (en) 2010-02-24 2013-02-19 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
DK2544536T3 (en) 2010-03-11 2019-02-04 Kempharm Inc FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
CN111329865A (zh) * 2020-03-30 2020-06-26 华东理工大学 奋乃静在制备治疗子宫内膜癌的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568837A (de) 1957-09-11 1900-01-01
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
GB1460713A (en) * 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3978216A (en) * 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3956493A (en) * 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
GB1540842A (en) * 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
CN1375287A (zh) * 2001-03-16 2002-10-23 王玉万 含氯氰碘柳胺或其钠盐的兽用混悬注射剂
KR20100097224A (ko) * 2001-09-27 2010-09-02 라모트 앳 텔 아비브 유니버시티 리미티드 접합된 항-정신병 약물 및 그의 용도

Also Published As

Publication number Publication date
EP1429844A2 (de) 2004-06-23
KR101238452B1 (ko) 2013-02-28
JP4521187B2 (ja) 2010-08-11
EP2275143A3 (de) 2011-01-26
JP2014015472A (ja) 2014-01-30
KR20120032547A (ko) 2012-04-05
KR20100097224A (ko) 2010-09-02
EP1429844A4 (de) 2006-06-07
JP2010090170A (ja) 2010-04-22
EP2275143A2 (de) 2011-01-19
MXPA04002912A (es) 2004-07-05
CN100558365C (zh) 2009-11-11
ES2379544T3 (es) 2012-04-27
ES2399977T3 (es) 2013-04-04
KR100996239B1 (ko) 2010-11-23
WO2003026563A9 (en) 2004-04-22
CA2461663A1 (en) 2003-04-03
EP2275143B1 (de) 2012-12-19
WO2003026563A3 (en) 2004-03-18
IL161083A0 (en) 2004-08-31
CN101445494A (zh) 2009-06-03
KR20090130150A (ko) 2009-12-17
JP2005503423A (ja) 2005-02-03
WO2003026563A2 (en) 2003-04-03
KR20040062554A (ko) 2004-07-07
CN1596141A (zh) 2005-03-16
IL202291A0 (en) 2011-07-31
EP1429844B1 (de) 2012-01-18

Similar Documents

Publication Publication Date Title
ATE541588T1 (de) Konjugat von perphenazin und gaba und seine verwendungen
DE60238255D1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
BR9904998A (pt) Derivados de hidroxamida do ácido 5-oxo-pirrolidina-2-carboxìlico
ES2118283T3 (es) Derivados de acidos benzofuranil- y -tiofenil-alcanocarboxilicos.
DE69739415D1 (de) Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten
TNSN07148A1 (en) (biphenyl) carboxylic acids and derivatives thereof
DE69023171D1 (de) Kondensierte heterozyklische Verbindungen, ihre Herstellung und Verwendung.
RS20050287A (en) Ruthenium complexes as (pre) catalysts for metathesis reactions
DE60329210D1 (en) Camptothecin-carboxylat-formulierungen
ATE508173T1 (de) Russ
ES2105953B1 (es) Perfeccionamientos en el objeto de la patente de invencion 9102594 por procedimiento de obtencion de compuestos derivados de piridina.
BR0317731A (pt) Compostos de ácido cicloalqueno dicarboxìlicos como agentes antiinflamatórios, imunomoduladores e antiproliferativos
DE60001487D1 (de) Polynalbuphinderivat
BR9105629A (pt) Composicao agroquimica,e,processo para preparar ou formular uma composicao agroquimica
BR0208131A (pt) Derivados biguanida
DE60003795D1 (de) Sulfofukosylacylglycerin-derivate und ihre anwendung als medikamente
ATE228134T1 (de) Kondensierte pyrimidinderivate und diese enthaltende pharmazeutische zubereitungen
KR910002450A (ko) 당뇨병 치료용 제약 조성물
DE50104100D1 (de) Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c
FR2709128A1 (fr) Procédé de préparation de Buspiron de haute pureté et de son chlorhydrate.
ATE354376T1 (de) Zusammensetzungen für die elektroporation
ATE290058T1 (de) Zusammensetzungen von duftstoffvorstufen und verfahren zum hervorbringen von duftstoffen
GT200300260A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
GT200200137A (es) Pirrolo [2.1-a] dihidroisoquinolinas
KR950016752A (ko) 피페라지닐 퀴놀론 카르복실산의 고농도 용액